Short Interest in agilon health, inc. (NYSE:AGL) Expands By 10.5%

agilon health, inc. (NYSE:AGL – Get Rating) was the recipient of a large increase in short interest in the month of December. As of December 30th, there was short interest totalling 27,690,000 shares, an increase of 10.5% from the December 15th total of 25,060,000 shares. Based on an average trading volume of 1,830,000 shares, the short-interest ratio is currently 15.1 days. Currently, 13.3% of the shares of the company are sold short.

agilon health Stock Up 0.4 %

Shares of AGL opened at $20.50 on Tuesday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.48 and a current ratio of 2.48. agilon health has a one year low of $14.36 and a one year high of $28.36. The stock has a market capitalization of $8.44 billion, a price-to-earnings ratio of -78.85 and a beta of 0.80. The stock has a 50 day moving average price of $17.43 and a 200 day moving average price of $20.89.

agilon health (NYSE:AGL – Get Rating) last issued its quarterly earnings results on Thursday, November 3rd. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.02). agilon health had a negative return on equity of 9.31% and a negative net margin of 4.30%. The firm had revenue of $694.86 million for the quarter, compared to analysts’ expectations of $651.24 million. Equities research analysts forecast that agilon health will post -0.21 earnings per share for the current fiscal year.

Insider Activity at agilon health

In other agilon health news, insider Benjamin Kornitzer sold 5,396 shares of the stock in a transaction dated Friday, January 20th. The stock was sold at an average price of $19.92, for a total transaction of $107,488.32. Following the sale, the insider now directly owns 10,426 shares of the company’s stock, valued at approximately $207,685.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other agilon health news, insider Benjamin Kornitzer sold 5,396 shares of the stock in a transaction dated Friday, January 20th. The stock was sold at an average price of $19.92, for a total transaction of $107,488.32. Following the sale, the insider now directly owns 10,426 shares of the company’s stock, valued at approximately $207,685.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Benjamin Shaker sold 20,723 shares of the stock in a transaction dated Wednesday, January 18th. The stock was sold at an average price of $19.78, for a total value of $409,900.94. Following the sale, the insider now directly owns 25,625 shares in the company, valued at $506,862.50. The disclosure for this sale can be found here. Insiders have sold a total of 39,613 shares of company stock valued at $746,114 in the last ninety days. Company insiders own 3.30% of the company’s stock.

Institutional Trading of agilon health

Large investors have recently made changes to their positions in the company. Treasurer of the State of North Carolina increased its position in shares of agilon health by 28.7% during the second quarter. Treasurer of the State of North Carolina now owns 79,157 shares of the company’s stock worth $1,728,000 after purchasing an additional 17,668 shares in the last quarter. Summit Financial Strategies Inc. purchased a new stake in agilon health in the 3rd quarter valued at $780,000. Level Financial Advisors Inc. purchased a new stake in agilon health in the 2nd quarter valued at $289,000. TriaGen Wealth Management LLC purchased a new stake in agilon health in the 3rd quarter valued at $296,000. Finally, State of New Jersey Common Pension Fund D purchased a new stake in agilon health in the 2nd quarter valued at $2,939,000.

Wall Street Analyst Weigh In

AGL has been the subject of a number of analyst reports. The Goldman Sachs Group reduced their price target on agilon health from $38.00 to $34.00 and set a “buy” rating for the company in a report on Tuesday, November 15th. Stifel Nicolaus initiated coverage on agilon health in a research report on Thursday, December 8th. They issued a “buy” rating and a $23.00 price objective for the company. SVB Leerink cut their price objective on agilon health from $33.00 to $30.00 and set an “outperform” rating for the company in a research report on Friday, November 4th. Finally, Wells Fargo & Company cut their price objective on agilon health from $28.00 to $22.00 and set an “overweight” rating for the company in a research report on Tuesday, November 15th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, agilon health has an average rating of “Moderate Buy” and an average target price of $28.38.

agilon health Company Profile

(Get Rating)

agilon health, inc. offers healthcare services for seniors through primary care physicians in the communities of the United States. As of December 31, 2021, it served approximately 238,000 senior members, which included 186,300 medicare advantage members and 51,700 medicare fee-for-service beneficiaries.